首页> 美国卫生研究院文献>other >Exome Sequencing in Classic Hairy Cell Leukaemia Reveals Widespread Variation in Acquired Somatic Mutations between Individual Tumours Apart from the Signature BRAF V(600)E Lesion
【2h】

Exome Sequencing in Classic Hairy Cell Leukaemia Reveals Widespread Variation in Acquired Somatic Mutations between Individual Tumours Apart from the Signature BRAF V(600)E Lesion

机译:在经典的毛细胞白血病中的外显子组测序揭示了除特征性BRAF V(600)E病变外的单个肿瘤之间获得性体细胞突变的广泛变异。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In classic Hairy cell leukaemia (HCLc), a single case has thus far been interrogated by whole exome sequencing (WES) in a treatment naive patient, in which BRAF V(600)E was identified as an acquired somatic mutation and confirmed as occurring near-universally in this form of disease by conventional PCR-based cohort screens. It left open however the question whether other genome-wide mutations may also commonly occur at high frequency in presentation HCLc disease. To address this, we have carried out WES of 5 such typical HCLc cases, using highly purified splenic tumour cells paired with autologous T cells for germline. Apart from BRAF V(600)E, no other recurrent somatic mutation was identified in these HCLc exomes, thereby excluding additional acquired mutations as also prevalent at a near-universal frequency in this form of the disease. These data then place mutant BRAF at the centre of the neoplastic drive in HCLc. A comparison of our exome data with emerging genetic findings in HCL indicates that additional somatic mutations may however occur recurrently in smaller subsets of disease. As mutant BRAF alone is insufficient to drive malignant transformation in other histological cancers, it suggests that individual tumours utilise largely differing patterns of genetic somatic mutations to coalesce with BRAF V(600)E to drive pathogenesis of malignant HCLc disease.
机译:在经典的毛细胞白血病(HCLc)中,迄今为止,在未接受治疗的患者中,有一个病例已通过全外显子组测序(WES)进行了询问,其中BRAF V(600)E被鉴定为获得性体细胞突变,并证实发生在附近通常通过常规的基于PCR的队列筛选以这种疾病形式出现。然而,对于呈递性HCLc疾病,是否还会普遍发生其他全基因组突变也存在疑问。为了解决这个问题,我们使用高度纯化的脾脏肿瘤细胞与自体T细胞配对作为种系,进行了5例典型HCLc病例的WES。除了BRAF V(600)E,在这些HCLc外显子组中未发现其他复发性体细胞突变,从而排除了其他获得性突变,该突变也以这种疾病的近乎普遍的频率普遍存在。然后,这些数据将突变型BRAF置于HCLc肿瘤驱动的中心。将我们的外显子组数据与HCL中新出现的遗传发现进行比较表明,其他疾病可能会在较小的亚型中反复发生。由于仅BRAF突变体不足以驱动其他组织学癌变中的恶性转化,因此表明单个肿瘤利用遗传上的体细胞突变的模式大不相同,以与BRAF V(600)E结合以驱动恶性HCLc疾病的发病机理。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号